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Abstract
Background: Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry (MS) has been demonstrated
to be useful for molecular profiling of common solid tumors. Using recently developed MALDI matrices for lipid
profiling, we evaluated whether direct tissue MALDI MS analysis on proteins and lipids may classify human breast
cancer samples according to the intrinsic subtype.
Methods: Thirty-four pairs of frozen, resected breast cancer and adjacent normal tissue samples were analyzed
using histology-directed, MALDI MS analysis. Sinapinic acid and 2,5-dihydroxybenzoic acid/a-cyano-4-
hydroxycinnamic acid were manually deposited on areas of each tissue section enriched in epithelial cells to
identify lipid profiles, and mass spectra were acquired using a MALDI-time of flight instrument.
Results: Protein and lipid profiles distinguish cancer from adjacent normal tissue samples with the median
prediction accuracy of 94.1%. Luminal, HER2+, and triple-negative tumors demonstrated different protein and lipid
profiles, as evidenced by permutation P values less than 0.01 for 0.632+ bootstrap cross-validated misclassification
rates with all classifiers tested. Discriminatory proteins and lipids were useful for classifying tumors according to the
intrinsic subtype with median prediction accuracies of 80.0-81.3% in random test sets.
Conclusions: Protein and lipid profiles accurately distinguish tumor from adjacent normal tissue and classify breast
cancers according to the intrinsic subtype.
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Background
Proteomics research is actively being performed to find
biomarkers for common solid tumors [1,2] including
breast cancer [3-5]. Matrix-assisted laser desorption/
ionization (MALDI) mass spectrometry (MS) has been
demonstrated to be useful for histological classification
[6-10] and outcome prediction [11] of common solid
tumors.
In this approach, thin sections of frozen tissues are
obtained from surgical resections or biopsies and mass
spectra are obtained from discrete locations on the tissue.
In a study of human breast cancer samples, protein pro-
files obtained from histology-directed MALDI MS
differentiate invasive breast cancers from ductal carci-
noma in situ and normal breast epithelium [12]. In
another report, MALDI imaging MS classified breast
cancer tissue specimens according to HER2 status [13].
Accumulating evidence suggests that alteration in lipid
composition is associated with breast carcinogenesis
[14-16]. Recently, cancer-associated lipid alteration was
extensively characterized using ultra performance liquid
chromatography-MS analysis of tissue lysate from breast
cancer tissue specimens [16]. These reports suggest that
monitoring lipid composition in clinical samples may
provide an opportunity for breast cancer diagnosis.
Breast cancer is the second most commonly diagnosed
cancer in women worldwide [17]. Recent advances in the
development of matrices for MALDI MS made it possible
to directly probe tissues to profile lipid composition and
distribution [18,19]. Using frozen surgical breast cancer
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ogy-directed MALDI MS analysis of protein and lipid to
evaluate whether this approach can differentiate and clas-
sify breast cancers. Here we demonstrate that protein and
lipid MALDI MS profiles accurately differentiate breast
cancers from normal epithelium, and classify breast
tumors according to their intrinsic subtype.
Methods
Collecting and processing clinical material and protein
MALDI MS analysis
Thirty-four pairs of breast cancer and adjacent normal
tissue samples were collected at the time of surgery, with
informed consent and institutional review board approval,
from breast cancer patients undergoing surgery at
National Cancer Center in Korea from 2001 to 2010, and
stored in liquid nitrogen until analysis. Eleven samples
were excluded by spectra quality filter of ClinProTools
(version 2.2, Bruker Daltonics). Additional 21 samples
were excluded because of inadequate (< 50%) tumor con-
tent. These excluded samples were not different from sam-
ples analyzed in this study in patient age or intrinsic
subtype. Breast cancer intrinsic subtypes were classified
according to an immunohistochemistry (IHC) surrogate
panel [20,21] as follows: luminal [estrogen receptor (ER)
positive and/or progesterone receptor (PR) positive],
HER2+ [HER2+ regardless of hormone receptor status],
and triple-negative [ER-, PR-, and HER2-]. A cut-off value
of 1% or more of positively stained nuclei was used to
define ER and PR positivity. HER2 was scored as 0-3+
according to the method recommended for the HercepT-
est (Dako, Glostrup, Denmark). The cases with IHC scores
of 3+ or ERBB2 gene amplification by fluorescence in situ
hybridization (FISH) were considered positive for HER2.
Thin (10 μm) sections were obtained from the frozen
tissues using a cryostat (Leica CM 3050S, Leica Microsys-
tems Inc., Bannockburn, IL). Multiple (three to seven)
serial sections were obtained from each tissue. One sec-
tion was affixed to a standard glass slide, and then stained
with hematoxylin and eosin (H&E). The other sections
were thaw-mounted onto an indium tin oxide (ITO) slide
(HST Inc., Newark, NJ), desiccated in vacuum for 20
min, and washed with graded ethanol solutions (70%,
90%, and 95% ethanol for 30 sec each) for subsequent
protein MALDI MS analysis. Sinapinic acid (SA) was
used as the protein MALDI matrix and prepared as a 20
mg/ml solution in 50:50 acetonitrile: 0.1% trifluoroacetic
acid (TFA). Using a micropipette, 250 nl of the matrix
was manually deposited twice per spot. The H&E-stained
serial section was then evaluated by a pathologist, who
confirmed that entire H&E section of tumor samples had
at least 50% tumor content. Mass spectra were acquired
using an Autoflex III (Bruker Daltonics, Bremen,
Germany) MALDI TOF equipped with a SmartBeam
laser (Nd:YAG, 355 nm) and run using a linear-mode
acquisition method optimized for 2-30 kDa, a laser
frequency of 200 Hz, and a delay time of 7 ns. A total of
400 spectra were acquired at each spot position.
Lipid MALDI MS analysis
For lipid MALDI MS analysis, the binary matrix solution
was prepared by dissolving 7 mg each of 2, 5-dihydroxy-
benzoic acid (DHB) and a-cyano-4-hydroxycinnamic acid
(CHCA) in 1 mL of 70% methanol plus 0.1% TFA and 1%
piperidine [19]. Under the guidance of the same H&E-
stained adjacent section, the binary matrix (250 nl × 2)
was manually deposited on the tumor-rich area of cryosec-
tions that were thaw-mounted onto ITO slides. Mass
spectra were acquired both in positive- and negative-ion
reflector modes, using an Autoflex III (Bruker Daltonics)
TOF equipped with a SmartBeam laser and run using a
linear-mode acquisition method optimized for 500-1,200
Da, a laser frequency of 200 Hz (3,000 consecutive laser
shots), and a delay time of 0 ns. Before each data acquisi-
tion, an external calibration was conducted using lipid-
mixed calibration standards with m/z ranges of 674-834
Da (positive ion mode) and 564-906 Da (negative ion
mode).
MALDI LIFT (MS/MS) analysis was directly performed
on the tissue section after MALDI MS. LIFT data and
some lipid databases http://lipidsearch.jp or http://www.
lipidmaps.org were used to facilitate and confirm the
assignment of phospholipid species.
Data Processing and Statistical Analysis
ClinProTools was used for baseline subtraction, spectral
recalibration, and spectral area calculation. A resolution of
300 was applied to the peak detection method. The Top
Hat baseline with 10% minimal baseline width was used
for baseline subtraction. Data reduction was performed at
a factor of four. Spectra were recalibrated with a maximal
peak shift of 2,000 ppm between reference and peak
masses. The value of the “% Match to Calibrant Peaks”
parameter was set to 20%. Spectra that were not recalibra-
table were excluded. All data with signal-to-noise ratios >
5 were acquired, and the peak area was used for peak cal-
culation with zero level integration. An average peak list
was set up for each tissue sample by choosing peaks on
the calculated total average spectrum for each tissue sam-
ple to create one average spectrum per patient. Peaks with
the highest intensity in each ion mode (m/z = 616.23 and
539.53 in positive and negative ion modes respectively)
were identified as non-lipid molecules and therefore
excluded from subsequent analysis. Average-normalized
datasets (i.e., protein, positive mode-lipid, and negative-
mode lipid datasets) were then combined into a single
dataset and subjected to statistical analysis using BRB-
ArrayTools (NCI, version 3.8) [22]. A principal component
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Page 2 of 9analysis (PCA) plot was generated using multi-dimen-
sional scaling analysis of BRB-ArrayTools, which graphi-
cally represents correlation coefficients among samples
without forcing the samples into specific clusters. The
three primary principal components were used as the axes
for the 3-dimensional scaling representation. Class com-
parison and class prediction analyses were also performed
using BRB-ArrayTools. The class comparison analysis
computed the F-test for each peak, and listed peaks differ-
entially expressed among the classes at selected statistical
significance level. Then, it performed random permuta-
tions of the class labels. For each random permutation, all
F-tests were re-computed for each peak. The class com-
parison tool computed the proportion of the random per-
mutations that gave as many peaks significant at the
selected level of significance as were found by comparing
the true class labels. Protein and lipid profiles of the
classes were considered different if this probability (desig-
nated as Permutation P value) was calculated < 0.05.
To evaluate whether classes have different protein and
lipid profiles, class prediction analyses were performed
using all samples as a training set. The 0.632+ bootstrap
cross-validated misclassification rates was computed for
all classifier functions (compound covariate predictor,
diagonal linear discriminant analysis, 1- and 3-nearest
neighbors, nearest centroid, and support vector machine)
in the training set. Then, class labels were randomly
shuffled and the cross-validated misclassification rate was
computed for each random dataset. Permutation P value,
which is defined as the proportion of random datasets
that give as small misclassification rate as is obtained
with real class labels, was then calculated. MALDI MS
p r o f i l e so ft h ec l a s s e sw e r ec onsidered different if this
permutation P value was < 0.05.
To estimate the predictive power of discriminatory
peaks, the class prediction analyses were also performed
by randomly dividing the whole sample into two (training
and test) subsets at 1-to-1 ratio. Randomization was per-
formed using nQuery Advisor software (version 7.0, Statis-
tical Solutions, Saugus, MA).
Results
MALDI MS analyses were performed for 34 pairs of retro-
spective surgical tissue samples (34 breast cancers and 34
adjacent normal tissue samples). Adjacent normal tissue
samples were collected at least 2 cm apart from the cancer
margin. Table 1 summarizes the clinico-pathological char-
acteristics of analyzed tissue samples. There were 30 ade-
nocarcinomas (luminal (n = 18), HER2+ (n = 7), and
triple-negative (n = 5)), and 4 metaplastic carcinomas. In
16 out of 34 breast cancer samples (47.1%), the entire sam-
ple had > 50% tumor content. In the remaining 18 samples
(52.9%), the pathologist marked the hematoxylin and eosin
(H&E) slide at the tumor-rich (> 50% tumor content) area,
being careful to deposit the matrix within the boundary of
the marked tumor-rich area (Additional File 1, Figure S1).
Mass spectra were acquired on individual spots for each
tissue section, and these spectra were averaged together
after pre-processing to create one average spectrum per
patient. The average spectra were composed of 2 to 11
individual protein measurements for cancer samples (with
a median value of 5), and 2 to 10 individual protein
Table 1 Clinico-pathological characteristics
Age, yr
Range 33-73
Median 45
Gender
Female 34 (100%)
AJCC Stage
IA 6 (17.6%)
IIA 16 (47.1%)
IIB 1 (2.9%)
IIIA 9 (26.4%)
IIIB 2 (5.9%)
Location of primary tumor
Unilateral 34 (100%)
Right 18 (52.9%)
Left 16 (47.1%)
Bilateral 0
Histologic classification
Adenocarcinoma 30 (88.2%)
Ductal 26 (86.7%)
Lobular 1 (3.3%)
Mixed ductal and lobular 1 (3.3%)
Mucinous 2 (6.6%)
Metaplastic 4 (11.7%)
Immunohistochemistry
Estrogen receptor (ER)
Positive 24 (70.6%)
Negative 10 (29.4%)
Progesterone receptor (PR)
Positive 26 (76.5%)
Negative 8 (23.5%)
HER2
Positive 14 (41.2%)
Negative 20 (58.8%)
Ki67
< 15% 14 (41.2%)
≥15% 20 (58.8%)
Intrinsic subtype
Adenocarcinoma 30 (88.2%)
Luminal (ER+ and/or PR+) 18 (60.0%)
HER2 (HER2+ regardless of ER status) 7 (23.3%)
Triple negative (ER-, PR-, and HER2-) 5 (16.7%)
Metaplastic 4 (11.7%)
AJCC, American Joint Committee on Cancer (7
th Edition)
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ian value of 5). The average spectra were composed of 3 to
8 individual lipid measurements (with a median value of 4)
for both cancer and normal samples. It was possible that
same tissue area was profiled multiple times (up to three
spots) from different tissue sections loaded on different
ITO slides. Individual measurements were averaged to
minimize intra-sample variability. Post-spectral processing
identified 85 protein and 144 lipid features (78 for the
positive ion mode and 66 for the negative ion mode)
across the entire mass range for all of the samples studied
(Figure 1).
Cancer versus adjacent normal breast tissue
A principal component analysis (PCA) plot graphically
demonstrated that cancer and adjacent normal samples
were separately clustered ina nu n s u p e r v i s e da n a l y s i s
(Figure 2A). When a class comparison analysis was per-
formed using BRB-ArrayTools, the proportion of the
random permutations that gave as many significant
peaks at a feature selection of P <1 0
-5 as were found by
comparing the true class labels (cancer vs normal) was <
0.001, strongly suggesting that the cancer and normal
tissue samples have significantly different protein and
lipid profiles (Table 2). Class prediction analysis was
subsequently performed after randomly dividing the
entire set of samples into two groups at 1-to-1 ratio. At
a feature selection P < 0.001, the median class predic-
tion accuracy in test sets was 94.1% for all classifiers
tested, in 100 random training-to-test partitions. Thus,
breast cancer and adjacent normal tissues have clearly
different protein and lipid profiles.
To evaluate whether patients’ age affects cancer-asso-
ciated protein and lipid alteration, the cancer/normal
peak area ratio was compared between older (≥50 years,
n = 10) and younger (< 50 years, n = 24) age groups at
feature selection P < 0.05, using class comparison algo-
rithm of BRB-ArrayTools. The probability of getting as
many significant peaks by chance as was obtained with
real class labels, if there are no real differences between
Figure 1 Average mass spectra for proteins (A) and lipids (B) obtained in the positive ion mode from breast cancer and adjacent
normal tissue. Overlays of cancer and normal tissue mass spectra are shown below.
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and lipid alteration was not significantly different
between older and younger age groups.
Classification according to intrinsic subtype
According to the PCA analysis, cancer samples were
clustered according to their intrinsic subtypes (Figure
2B). Class comparison was performed between intrinsic
subtypes that were defined by immunohistochemistry
(luminal [ER+ and/or PR+] vs HER2 [HER2 +] vs triple-
negative [ER-, PR-, and HER2-]. At a feature selection
P < 0.001, 19 peaks were significantly different among
subtypes (Table 3). The probability of getting at least 19
peaks significantly by chance (at the 0.001 level) with no
real differences between the classes was 0.002. For class
prediction analysis, all 30 cancer samples were first used
as a training set. At a feature selection P <0 . 0 0 1 ,
permutation P values for 0.632+ bootstrap cross-vali-
dated misclassification rates were < 0.01 for all classifiers
tested. These results indicate that breast tumor intrinsic
types have different protein and lipid profiles. When
these analyses were performed separately in protein and
lipid datasets, lipid profiles demonstrated consistently
lower permutation P values for cross-validated misclassi-
fication rate, across feature selection P values ranging
0.001 to 0.05 (data not shown).
We then planned to estimate the predictive power of
discriminatory proteins and lipids in training-to-test par-
titions, although this analysis is limited by the sample
size. At a feature selection P < 0.05, the median predic-
tion accuracy in test sets ranged from 80% to 81.3%
(80%, 81.3%, 80%, and 80%, for diagonal linear discrimi-
nant analysis, 1-nearest neighbor, 3-nearest neighbors,
and nearest centroid, respectively), in 100 random
Figure 2 Principal component analysis and Intensity Profile. (A) A principal component analysis plot for 34 pairs of breast cancer (shown in
red) and adjacent normal (shown in green) tissue samples, which graphically represents 1-correlation distances among samples. Each sphere
represents a single sample, and samples whose protein expression profiles are very similar are shown close together. (B) A principal component
analysis plot for luminal (shown in red), HER2+ (shown in green), and triple-negative breast adenocarcinoma samples (shown in blue) (C) A
principal component analysis plot for metaplastic carcinomas (shown in green) and adenocarcinomas (shown in red). (D) Intensity profile for a
representative lipid (m/z = 732.58 in the positive ion mode) differentially expressed among intrinsic subtypes. The average peak of the intrinsic
subtype (left) and all single peaks (right) are shown.
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listed in Table 3.
Metaplastic carcinoma vs adenocarcinoma
Metaplastic carcinoma is a unique breast cancer subtype,
characterized by distinct morphologic feature and poor
p r o g n o s i s[ 2 3 ] .T of u r t h e re v aluate whether protein and
lipid profiles could distinguish biological feature, we com-
pared metaplastic carcinomas (n = 4) with adenocarcino-
mas (n = 30) for protein and lipid profiles. According to
PCA analysis, metaplastic carcinomas were clearly sepa-
rated from adenocarcinomas (Figure 2C). For class predic-
tion analysis, all 34 cancer samples were used as a training
set, given the small number of metaplastic carcinomas. At
a feature selection P < 0.001, permutation P values for
0.632+ bootstrap cross-validated misclassification rates
were < 0.05 for all classifiers tested (0.01, < 0.01, < 0.01,
< 0.01, 0.01, and < 0.01, for the compound covariate pre-
dictor, diagonal linear discriminant analysis, 1-nearest
neighbor, 3-nearest neighbors, nearest centroid, and sup-
port vector machine, respectively). Although sample size is
small, metaplastic carcinomas appear to have unique pro-
tein and lipid profiles.
Discussion
This study demonstrates that histology-directed MALDI
MS analysis of lipids and proteins may differentiate
between cancerous and normal epithelium and among
intrinsic subtypes of breast cancer. Phosphatidylcholines
(PCs) {34:1} (m/z = 760.62 [M-H]
+ and 798.58 [M-K
+])
were found to be overexpressed in breast cancer. In our
previous publication [24], we demonstrated that cholan-
giocarcinomas and pancreatic cancers have increased PC
{34:1} (m/z = 760). We also validated the identity of the
PC {34:1} peak by comparing MS/MS spectra of [M+H]
+
ion (m/z 760) of 34:1-PC species found on a cholangio-
carcinoma sample with those of standard 18:1/16:0-PC
species [24]. This peak was also increased in our ovarian
cancer tissue samples as compared with adjacent normal
tissue (manuscript in preparation). Membrane phospholi-
pid composition influences the activity of membrane-
associated phospholipase A2 (PLA2) [25], which plays a
role in carcinogenesis [26], and that overexpression of
ChoKa1, which generates PC, is oncogenic [27].
More importantly, we have found that luminal, HER2+,
and triple-negative breast cancer subtypes have different
protein and lipid MALDI MS profiles. This result is con-
sistent with a previous report that protein MALDI ima-
ging MS classifies breast cancer tissue specimens
according to HER2 status [13]. Using similar tissue
MALDI MS technology, we confirmed and extended pre-
vious reports by identifying the intrinsic subtype-specific
protein and lipid profiles. Brozkova, et al.a l s or e p o r t e d
that SELDI-TOF MS could classify breast cancer tissue
Table 2 Peaks differentially expressed between cancer and adjacent normal tissue samples at a feature selection P <
10
-5
Overexpressed in cancer Underexpressed in cancer
m/z P Ratio
1 Assignment m/z p Ratio
1
6206.58 1.00E-07 1.6 5150.41 3.50E-06 0.9
7222.53 1.00E-06 1.4 7618.64 < 1E-10 0.6
8514.66 1.10E-06 1.4 9486.03 1.00E-07 0.7
11719.24 < 1E-07 1.8 16089.36 9.90E-06 0.6
12411.2 < 1E-07 2.1
n545.56 2.70E-06 0.5
p734.58 3.60E-06 2.0 PC {32:0} [M+H]
+ n554.49 4.00E-07 0.4
p741.62 < 1E-07 2.1 SM {d18:1/16:0} [M+K]
+ n568.56 9.60E-06 0.5
p760.62 2.90E-06 2.0 PC {34:1} [M+H]
+ n574.61 5.70E-06 0.7
p772.58 < 1E-07 1.8 PC {32:0} [M+K]
+ n594.5 1.00E-07 0.6
p798.58 < 1E-08 2.1 PC {34:1} [M+K]
+ n609.74 1.90E-06 0.4
n651.64 3.40E-06 0.5
n505.37 < 1E-09 5.3 n666.79 7.00E-07 0.5
n605.64 < 1E-10 5.3 n679.13 6.40E-06 0.5
n878.89 2.50E-06 0.6
n907.09 7.50E-06 0.5
n917.48 3.60E-06 0.5
n997.7 1.80E-06 0.5
1Ratio, cancer/normal
p, lipids identified in the positive ion mode
n, lipids identified in the negative ion mode
SM, Sphingomyelin
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subtypes [28]. Thus, our MALDI profiles contain infor-
mation about histopathological and biological feature of
this heterogeneous disease [29]. Molecular profiles we
identified are consistent with previous data generated via
different analysis platforms.W eh a v ef o u n dt h a tt r i p l e -
negative breast cancers overexpress PC {32:1} [M+H]
+
(m/z = 732.58) and PC {30:0} [M+H]
+ (m/z = 706.5),
compared with luminal and HER2 subtypes. According
to a recent report by Hilvo et al., these lipids are under-
expressed in ER-positive breast cancer tissue samples,
compared with ER-negative samples (P = 0.001 and P <
0.001, respectively) [16]. In our data, these lipids were
also positively correlated with ER negativity (P =0 . 0 2 9
and 0.002, respectively).
Notably, our relatively simple approach takes less ana-
lytic time and tissue amount than lysate-based proteo-
mics technologies used by aforementioned studies
[16,29], which provides a clear advantage as a possible
diagnostic aid, once our discriminatory profiles are vali-
dated in a larger dataset. Our novel two-matrix (SA and
DHB/CHCA) MALDI profiling offers additional layer of
molecular information, and, therefore, may possibly cap-
ture biological features of the breast cancer better than
one-matrix MALDI profiling. Conversely, our relatively
simple approach needs to be improved for obtaining
tumor cell-specific mass spectra to better profile complex
clinical material such as the needle biopsy of breast can-
cers, by using MALDI imaging MS [13] or a robotic spot-
ter that deposits micron-sized droplets of matrix [12].
Also, our study is limited by incomplete assignment of
discriminatory peaks using MS/MS, and by the sample
size which is sufficient for statistical significance yet rela-
tively small. Further studies on a larger scale are clearly
warranted to validate discriminatory protein and lipid
profiles identified by this proof-of-concept study.
Conclusions
Luminal, HER2+, and triple-negative breast cancer sub-
types have different protein and lipid MALDI MS pro-
files. Protein and lipid profiles identified by our novel
two-matrix (SA and DHB/CHCA) MALDI analyses are
sensitive and may capture biological features of the
breast cancer.
Additional material
Additional file 1: Procedures for MALDI MS analysis. A representative
cancer tissue cryosection, with the DHB/CHCA matrix applied at the
locations marked in the H&E section, is shown at the bottom. The H&E
section marked at discrete locations (enriched in tumor cells) using a red
color marker pen (center) and magnified (× 20) areas of the H&E-stained
section corresponding to matrix-loaded spots (top left and right) are
shown at the top.
Table 3 Peaks differentially expressed among intrinsic subtypes at a feature selection P < 0.001
mz p Relative peak intensity Assignment
Luminal HER2+ Triple-negative
p514.32 0.0006 2.2 3.8 2.0
p515.2 0.0007 1.7 2.8 1.3
p531.34 0.0002 1.3 2.4 1.1
p534.25 0.0001 1.8 3.0 1.5 PC {16:1} [M+H]
+
p535.22 0.0001 1.2 1.7 1.1
p578.67 0.0000 14.6 5.3 3.1
p644.33 0.0004 3.6 2.1 1.5
p678.32 0.0006 4.8 4.6 2.6
p706.52 0.0003 2.4 2.7 5.7 PC {30:0} [M+H]
+
p732.58 < 0.001 1.3 2.7 11.0 PC {32:1} [M+H]
+
n505.37 0.0001 13.2 90.5 78.1
n527.44 0.0005 4.5 1.6 1.6
n545.56 < 0.001 5.0 1.5 1.7
n552.56 0.0003 2.3 1.1 1.1
n554.49 < 0.001 3.8 1.2 1.2
n587.67 0.0009 4.3 1.6 1.7
n589.59 0.0002 3.6 1.4 1.4
n627.71 0.0008 4.7 1.9 2.1
n631.89 0.0005 2.5 1.3 1.2
1Ratio, cancer/normal
p, lipids identified in the positive ion mode
n, lipids identified in the negative ion mode
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